"the hospital � i don't know what to say. everyone was amazing," he said.
.
.
.
.
the obvious reason: their big-spending pharmaceutical advertisers would drop them like hot potatoes.
.
.
eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
. taking ustekinumab�a biologic that targets a different aspect of the immune system," gelfand said.
.
.
.